Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011114 · ClinicalTrials.gov registry record · NA
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
A NA study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT01011114 is a NA study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT01011114, a NA study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether cinacalcet, used in patients with secondary hyperparathyroidism to control excessive parathyroid hormone, can normalize low blood phosphorus that is commonly seen in patients who have had a kidney transplant.
Interventions
- DRUG Placebo
- DRUG Cinacalcet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-10-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011114
The ClinicalTrials.gov registry entry for NCT01011114 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01011114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011114 about?
NCT01011114 is a clinical study titled "Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant". The purpose of the study is to determine whether cinacalcet, used in patients with secondary hyperparathyroidism to control excessive parathyroid hormone, can normalize low blood phosphorus that is commonly seen in patients who have had a kidney transplant.
What is the current status of trial NCT01011114?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2009-11. Estimated completion is 2015-10-15.
What interventions are being tested in trial NCT01011114?
The interventions under investigation include: Placebo (DRUG), Cinacalcet (DRUG).
Who is sponsoring clinical trial NCT01011114?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.